Dermatological and gastrointestinal adverse reactions in ocrelizumab treated patients with multiple sclerosis: a case series
BackgroundAnti-CD20 therapies are widely used in patients with multiple sclerosis (pwMS). Recognition of rare adverse reactions to these therapies is therefore important.ObjectivesTo report dermatological and gastrointestinal adverse reactions in a single-center cohort of ocrelizumab treated pwMS.Me...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Langue: | anglais |
| Publié: |
09 March 2026
|
| In: |
Frontiers in immunology
Year: 2026, Volume: 17, Pages: 1-11 |
| ISSN: | 1664-3224 |
| DOI: | 10.3389/fimmu.2026.1753387 |
| Accès en ligne: | Verlag, kostenfrei, Volltext: https://doi.org/10.3389/fimmu.2026.1753387 Verlag, kostenfrei, Volltext: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1753387/full 
|
| Notes sur l'auteur: | Lena K. Höpner, Ella Marschall, Patrick Schindler, Vilmar Frauendorf, Michael Böhmig, Florian Rakers, Diana Karimi, Claudius Faber, Klemens Ruprecht and Carolin Otto |
| Résumé: | BackgroundAnti-CD20 therapies are widely used in patients with multiple sclerosis (pwMS). Recognition of rare adverse reactions to these therapies is therefore important.ObjectivesTo report dermatological and gastrointestinal adverse reactions in a single-center cohort of ocrelizumab treated pwMS.MethodsRetrospective analysis conducted at a multiple sclerosis outpatient clinic of Charité - Universitätsmedizin Berlin, Berlin, Germany, between March 2020 and February 2025.ResultsAmong 447 ocrelizumab treated pwMS, 8 (1.8%) developed dermatological adverse reactions after a median (range) of 20.5 (6-72) months following start of therapy, including lichen planus (n=2), rosacea (n=1), psoriatic arthritis (n=1), guttate psoriasis (n=1), psoriasis vulgaris (n=1), nail psoriasis (n=1) and palmoplantar psoriasis (n=1). Another 5 (1.1%) patients developed gastrointestinal adverse reactions 24 (0.25-77) months after starting therapy, including Crohn’s disease (n=1), toxic colitis (n=1), lymphocytic colitis (n=1), perforated appendicitis (n=1) and acute cholecystitis (n=1). Due to these adverse reactions, ocrelizumab was stopped in 7/13 patients. At last follow-up, adverse reactions had completely improved in 4/13, incompletely improved in 6/13, and persisted in 3/13 patients.ConclusionsClinicians should be aware of dermatological and gastrointestinal adverse reactions associated with ocrelizumab, which can develop from a few weeks up to six years after start of therapy. |
|---|---|
| Description: | Veröffentlicht: 09. März 2026 Gesehen am 15.05.2026 |
| Description matérielle: | Online Resource |
| ISSN: | 1664-3224 |
| DOI: | 10.3389/fimmu.2026.1753387 |